- MAIA Biotechnology (NYSE:MAIA) on Wednesday said that the National Institutes of Health [NIH] has awarded a $2.3 million grant for the expansion of its THIO-101 Phase 2 clinical trial evaluating ateganosine as a third-line treatment for patients with advanced non-small cell lung
MAIA Biotechnology awarded $2.3 million grant by NIH (MAIA:NYSE)
Byutsavmoradiya12@gmail.com
Sep 24, 2025